2026-01-17 - Analysis Report
**1. Company Overview and Divergence Analysis**
- Company Name: Planet Labs PBC
- Cumulative return of review stock = 496.64%
- Cumulative return of comparison stock (S&P 500, VOO) = 42.11%
- Divergence = 412.50

The review stock has significantly outperformed the comparison stock, with a divergence of 412.50% on the last day of the data.

**2. Recent Stock Price Fluctuations**
- Close = $28.78
- Last-market change = 6.2% ($1.77)
- 5-day SMA = $26.91
- 20-day SMA = $22.15
- 60-day SMA = $16.08

The stock has experienced a sharp rebound with a 6.2% increase, and its 5-day SMA is above the current price.

**3. RSI, PPO, MRI, and Expected Return Analysis**
- Market Risk Indicator (MRI) = 0.80 (Medium Risk)
- RSI = 95.73 (Overbought)
- PPO = 1.64 (Neutral)
- Hybrid Signal: Buy (Cash 0%)
- Expected Return (%) = -5.90% (Negative)

The stock is in an overbought state, and the MRI suggests medium risk. The expected return is negative, indicating that the stock may decline in the long term.

**4. News & Significant Events Analysis**
- Recent news highlights the stock's sharp increase due to positive events, including a 9-figure deal and earnout shares issuance.

**5. Analyst Opinions**
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
  - Opinions: 9
  - Target Price (avg/high/low): 23.70 / 30.00 / 12.30

Analysts are optimistic about the stock, with a consensus of "buy" and a target price range of 12.30 to 30.00.

**6. Recent Earnings Analysis**
| Quarter | EPS | Revenue |
|---------|-----|----------|
| 2025-10-28 | 0.82 | $2.21B |
| 2025-07-30 | 0.61 | $2.18B |
| 2025-04-29 | 0.64 | $2.14B |
| 2025-02-14 | 1.38 | $2.20B |
| 2024-10-25 | 1.08 | $2.04B |

The earnings reports show EPS ranging from 0.61 to 1.38, and revenue from $2.04B to $2.21B.

**7. Comprehensive Analysis (Summary of previous items)**

- Strong divergence with the comparison stock (496.64% vs 42.11%)
- Recent price fluctuations indicate a sharp rebound
- Overbought state with RSI = 95.73
- Medium risk according to MRI (0.80)
- Negative expected return (-5.90%)
- Analyst consensus: "buy" with a target price range of 12.30 to 30.00
- Earnings reports show a range of EPS and revenue

Consider this report for a comprehensive analysis of the stocks.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.